BDSX vs. CNTG, FLGT, CELC, CSTL, GRAL, SERA, PSNL, BNR, ENZ, and XGN
Should you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include Centogene (CNTG), Fulgent Genetics (FLGT), Celcuity (CELC), Castle Biosciences (CSTL), Grail (GRAL), Sera Prognostics (SERA), Personalis (PSNL), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), and Exagen (XGN). These companies are all part of the "medical laboratories" industry.
Centogene (NASDAQ:CNTG) and Biodesix (NASDAQ:BDSX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, community ranking, valuation, risk and analyst recommendations.
Centogene has a beta of -0.67, indicating that its share price is 167% less volatile than the S&P 500. Comparatively, Biodesix has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.
Centogene has a net margin of 0.00% compared to Centogene's net margin of -85.80%. Biodesix's return on equity of 0.00% beat Centogene's return on equity.
Biodesix has a consensus price target of $3.08, suggesting a potential upside of 78.78%. Given Centogene's higher probable upside, analysts plainly believe Biodesix is more favorable than Centogene.
Centogene has higher revenue and earnings than Biodesix.
Centogene received 12 more outperform votes than Biodesix when rated by MarketBeat users. However, 73.68% of users gave Biodesix an outperform vote while only 64.52% of users gave Centogene an outperform vote.
9.9% of Centogene shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 1.9% of Centogene shares are held by company insiders. Comparatively, 69.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Biodesix had 3 more articles in the media than Centogene. MarketBeat recorded 5 mentions for Biodesix and 2 mentions for Centogene. Centogene's average media sentiment score of 1.44 beat Biodesix's score of 1.43 indicating that Biodesix is being referred to more favorably in the news media.
Summary
Biodesix beats Centogene on 8 of the 14 factors compared between the two stocks.
Get Biodesix News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodesix Competitors List
Related Companies and Tools
Free BDSX Stock Alerts